HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

CRN safe nutrient intake

This article was originally published in The Tan Sheet

Executive Summary

Vitamin and Mineral Safety 2nd Edition provides "supportable data" on safe levels of vitamin and mineral intake that is "far preferable" to Recommended Daily Allowances at a time when Codex Alimentarius is debating science-based standards for supplement regulation, the Council for Responsible Nutrition announces July 30. The publication is a quantitative risk assessment meant to "identify the highest chronic supplemental intake of vitamins and minerals that can be confidently asserted to pose no risk for the majority of the normal adult population," according to author John Hathcock, PhD, VP-scientific & international affairs, who also wrote the first edition in 1997 (1"The Tan Sheet" July 28, 1997)...

You may also be interested in...



CRN suggests nutrient "safety approach" based on "no adverse effect level" values.

VITAMIN E "NO OBSERVED ADVERSE EFFECT LEVEL" OF 80 TIMES RDA PROPOSED BY CRN in a July 8 report entitled "Vitamin and Mineral Safety." The Council for Responsible Nutrition asserts in the report its long-held contention that the Recommended Dietary Allowances set forth by the Food & Nutrition Board of the National Academy of Sciences are "not a valid basis for identifying safe upper intakes of vitamins and minerals." The report provides alternative methods for identifying safe upper nutrient intakes based on the use of "No Observed Adverse Effect Level" (NOAEL) and "Lowest Observed Adverse Effect Level" (LOAEL) values for 25 specific nutrients

Deals In Depth: March 2021

BridgeBio Pharma’s affiliate QED Therapeutics granted and Helsinn Group exclusive global rights (excluding Greater China) to the FGFR1-3 inhibitor infigratinib in oncology and all other indications except skeletal dysplasias (including achondroplasia). BridgeBio could see up to $2.45bn in payments from the deal, including over $100m in up-front, regulatory, and launch payments, and the remainder in sales milestones. In the month’s top M&A, Amgen entered into an agreement to acquire fellow public biotech Five Prime Therapeutics for about $1.9bn, gaining Phase III-ready bemarituzumab for frontline advanced gastric or gastroesophageal junction cancer.  

The Growing GLP-1 Therapy Market

Novo Nordisk was not the first biopharmaceutical company to launch a GLP-1 therapy into the market for type 2 diabetes. In fact, Amylin Pharmaceutials’ and Eli Lilly’s Byetta (exenatide) beat Novo’s Victoza (liraglutide) to market by a full five years.  

Topics

UsernamePublicRestriction

Register

RS127501

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel